Artigos

Search for articles

BJO Oncology - Placeholder

Updates in the Management of Merkel Cell Carcinoma

ABSTRACT Merkel cell carcinomas are rare cutaneous malignancies with neuroendocrine features that affect elderly individuals with a history of chronic sun exposure and immunosuppression. More recently, a human viral pathogen, the Merkel cell polyomavirus, has been implicated in the carcinogenesis of this disease. Its particularly aggressive biological behavior, the delay...
BJO Oncology - Placeholder

Overview and different perspectives on possible treatments related to NUT carcinoma: a systematic review

ABSTRACT NUT carcinoma (midline testicular carcinoma nuclear protein) is a relatively new, rare, aggressive and underdiagnosed entity. Its sites of involvement are medial structures of the head and neck and mediastinum, but other sites may be affected, and even in so-called common structures, the clinical course may impress. The objective...
BJO Oncology - Placeholder

Narrative Review about Importance of Nutrition on Survivors and in the Prevention of Cancer

ABSTRACT Cancer is the second leading cause of death in Brazil. This study aimed to review the nutrition role in prevention and post-treatment of cancer as a health promoter. Regarding prevention, when analyzing lifestyle (obesity and physical activity), there was a positive correlation between body mass index and body fat...
BJO Oncology - Placeholder

Year in Review 2018 by the Brazilian Gastrointestinal Tumors Group - GTG: Gastrointestinal Tumors

ABSTRACT In 2018, there were some important trials presented over multiple international meetings. The objective of this article is to summarize the most important and practice changing studies in gastrointestinal oncology this year. Some studies in gastroesophageal, pancreatic, colorectal and anal canal have been selected, including adjuvant therapy in pancreatic...
BJO Oncology - Placeholder

Treatment of Advanced Prostate Cancer: Where Are We in 2019?

ABSTRACT In the last decade, important advances have been made in the treatment of metastatic prostate cancer, resulting in a better understanding of the biology underlying the disease, and in the approval of several therapeutic agents such as immunotherapy, new generation antiandrogens, cytotoxic chemotherapies, and radiopharmaceuticals. All these recent advances...